Form 8-K - Current report:
SEC Accession No. 0001558370-25-010785
Filing Date
2025-08-07
Accepted
2025-08-07 16:30:12
Documents
18
Period of Report
2025-08-07
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K adap-20250807x8k.htm   iXBRL 8-K 44214
2 EX-10.1 adap-20250807xex10d1.htm EX-10.1 42057
3 EX-10.2 adap-20250807xex10d2.htm EX-10.2 27301
4 GRAPHIC adap-20250807xex10d2001.jpg GRAPHIC 2489
5 GRAPHIC adap-20250807xex10d2002.jpg GRAPHIC 9125
6 GRAPHIC adap-20250807xex10d2005.jpg GRAPHIC 4096
7 GRAPHIC adap-20250807xex10d2006.jpg GRAPHIC 833
  Complete submission text file 0001558370-25-010785.txt   267864

Data Files

Seq Description Document Type Size
8 EX-101.SCH adap-20250807.xsd EX-101.SCH 3896
9 EX-101.LAB adap-20250807_lab.xml EX-101.LAB 15970
10 EX-101.PRE adap-20250807_pre.xml EX-101.PRE 10789
20 EXTRACTED XBRL INSTANCE DOCUMENT adap-20250807x8k_htm.xml XML 4866
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE United Kingdom
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE United Kingdom 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)